Literature DB >> 33215226

[Tumor biology of oropharyngeal carcinoma].

S Laban1, M Brand2, J Ezić2, J Doescher2, G Völkel3, H A Kestler3, C Brunner2, T K Hoffmann2.   

Abstract

BACKGROUND: Etiologically, oropharyngeal squamous cell carcinoma (OPSCC) can be divided into OPSCC caused by noxious agents and human papillomavirus (HPV)-driven carcinoma. These types differ with regard to clinical features and prognosis-differences which are rooted in the underlying molecular biology of the tumor.
OBJECTIVE: The aim of this work is to provide an overview of the molecular biological characteristics of the genetics, epigenetics, and immunology of OPSCC.
MATERIALS AND METHODS: A literature review was performed on a selection of genetic, epigenetic, and immunological factors characterizing OPSCC.
RESULTS: The understanding of genetic aberrations and their consequences for cancerogenesis and tumor biology is increasing. Epigenetic phenomena are complementing functional relationships. However, epigenetic mechanisms of gene regulation are complex and much research is still required in this field. Immunological aspects of cancer molecular biology have moved into the focus in light of recent advances in the field of immunotherapy.
CONCLUSION: The tumor biology of OPSCC is primarily defined by its HPV status. Additionally, HPV-independent genetic, epigenetic, and immunological signatures are being defined. From these advances, rationales for new treatment concepts may evolve.

Entities:  

Keywords:  Biomarkers, tumor; Epigenetics; Medical genetics; Molecular medicine; Oropharyngeal neoplasms

Mesh:

Year:  2020        PMID: 33215226     DOI: 10.1007/s00106-020-00964-4

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  63 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).

Authors:  Panagiotis Balermpas; Franz Rödel; Claus Rödel; Mechthild Krause; Annett Linge; Fabian Lohaus; Michael Baumann; Inge Tinhofer; Volker Budach; Eleni Gkika; Martin Stuschke; Melanie Avlar; Anca-Lidia Grosu; Amir Abdollahi; Jürgen Debus; Christine Bayer; Stefan Stangl; Claus Belka; Steffi Pigorsch; Gabriele Multhoff; Stephanie E Combs; David Mönnich; Daniel Zips; Emmanouil Fokas
Journal:  Int J Cancer       Date:  2015-07-30       Impact factor: 7.396

Review 3.  Regulation of chromatin by histone modifications.

Authors:  Andrew J Bannister; Tony Kouzarides
Journal:  Cell Res       Date:  2011-02-15       Impact factor: 25.617

Review 4.  A network-biology perspective of microRNA function and dysfunction in cancer.

Authors:  Cameron P Bracken; Hamish S Scott; Gregory J Goodall
Journal:  Nat Rev Genet       Date:  2016-10-31       Impact factor: 53.242

5.  Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer.

Authors:  Panagiotis Balermpas; Franz Rödel; Christian Weiss; Claus Rödel; Emmanouil Fokas
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110

6.  Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer.

Authors:  Martina A Broglie; Wolfram Jochum; Angelika Michel; Tim Waterboer; Diana Foerbs; René Schoenegg; Sandro J Stoeckli; Michael Pawlita; Dana Holzinger
Journal:  Oral Oncol       Date:  2017-05-25       Impact factor: 5.337

7.  Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens.

Authors:  Vera Balz; Kathrin Scheckenbach; Karl Götte; Ulrike Bockmühl; Iver Petersen; Henning Bier
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

8.  Disruption of NSD1 in Head and Neck Cancer Promotes Favorable Chemotherapeutic Responses Linked to Hypomethylation.

Authors:  Nam Bui; Justin K Huang; John Paul Shen; Ana Bojorquez-Gomez; Katherine Licon; Kyle S Sanchez; Sean N Tang; Alex N Beckett; Tina Wang; Wei Zhang; Jason F Kreisberg; Trey Ideker
Journal:  Mol Cancer Ther       Date:  2018-04-10       Impact factor: 6.261

9.  Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer.

Authors:  P Balermpas; Y Michel; J Wagenblast; O Seitz; C Weiss; F Rödel; C Rödel; E Fokas
Journal:  Br J Cancer       Date:  2013-10-15       Impact factor: 7.640

10.  Enhancer methylation dynamics contribute to cancer plasticity and patient mortality.

Authors:  Rachel E Bell; Tamar Golan; Danna Sheinboim; Hagar Malcov; David Amar; Avi Salamon; Tamar Liron; Sahar Gelfman; Yankel Gabet; Ron Shamir; Carmit Levy
Journal:  Genome Res       Date:  2016-02-23       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.